Chen Franco-Yehuda
2023
In 2023, Chen Franco-Yehuda earned a total compensation of $375.2K as CFO at Pluristem Therapeutics, a 38% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $66,062 |
|---|---|
| Salary | $284,096 |
| Other | $25,081 |
| Total | $375,239 |
Franco-Yehuda received $284.1K in salary, accounting for 76% of the total pay in 2023.
Franco-Yehuda also received $66.1K in non-equity incentive plan and $25.1K in other compensation.
Rankings
In 2023, Chen Franco-Yehuda's compensation ranked 2,340th out of 3,006 executives tracked by ExecPay. In other words, Franco-Yehuda earned more than 22.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,340 out of 3,006 | 22nd |
Division Manufacturing | 1,318 out of 1,650 | 20th |
Major group Chemicals And Allied Products | 781 out of 918 | 15th |
Industry group Drugs | 762 out of 881 | 14th |
Industry Biological Products, Except Diagnostic Substances | 192 out of 213 | 10th |
Source: SEC filing on May 1, 2024.
Franco-Yehuda's colleagues
We found one more compensation record of an executive who worked with Chen Franco-Yehuda at Pluristem Therapeutics in 2023.
2023
Yaky Yanay
Pluristem Therapeutics
Chief Executive Officer
News
Pluristem Therapeutics CEO Yaky Yanay's 2023 pay jumps 111% to $2.7M
May 1, 2024
Pluristem Therapeutics CEO Yaky Yanay's 2022 pay falls 86% to $1.3M
February 27, 2023
Pluristem Therapeutics Chairman Zami Aberman's 2020 pay falls 54% to $501K
April 8, 2021
Pluristem Therapeutics Chairman Zami Aberman's 2019 pay jumps 85% to $1.1M
May 20, 2020